Which Hospital in China Offers CAR-T Therapy: Costs, Options, and Access

by China Medical Services

When 52-year-old Daniel from London heard “refractory diffuse large B-cell lymphoma,” his oncologist had already outlined the next steps. Standard chemotherapy had stopped working. The conversation turned to chimeric antigen receptor T-cell therapy — CAR-T. Then came the second shock: the price tag at a leading UK cancer center. Daniel started typing into Google: CAR-T therapy cost China. He is not alone. Every week, patients and families from Europe, the Middle East, and North America search for the same thing — a way to access this breakthrough treatment without depleting a lifetime of savings.

This article explains where CAR-T therapy is offered in China, what it costs, how the process works for international patients, and which hospitals have the strongest track records. No hype. Just the facts you need to make an informed decision.

The Problem: A Breakthrough Treatment That Most Patients Cannot Afford

CAR-T therapy has transformed outcomes for certain blood cancers. For patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the ZUMA-1 trial showed an objective response rate of 82%, with 58% achieving a complete response. For acute lymphoblastic leukemia (ALL) in children and young adults, the ELIANA trial reported an overall remission rate of 81% within three months. These are staggering numbers for patients who had exhausted conventional options.

But the financial reality is brutal. In the United States, the list price for a single CAR-T infusion — just the product, not including hospitalization, managing side effects, or physician fees — ranges from $373,000 for tisagenlecleucel (Kymriah) to $475,000 for axicabtagene ciloleucel (Yescarta). When you add three to six weeks of inpatient monitoring, ICU stays for cytokine release syndrome (CRS), and follow-up care, total costs routinely exceed $700,000. Even with insurance, many families face six-figure out-of-pocket exposure. In the UK, access through the NHS is tightly rationed. In Canada and Australia, wait times for approved CAR-T products can stretch for months — time that relapsed lymphoma patients simply do not have.

That search for CAR-T therapy cost China is not about bargain hunting. It is about survival.

Why China Has Emerged as a Global Hub for CAR-T Therapy

Clinical Volume and Research Intensity

China now runs more CAR-T clinical trials than any other country. As of 2024, Chinese institutions had registered over 600 CAR-T clinical trials on ClinicalTrials.gov — more than the United States. This is not a peripheral player in cell therapy. It is the largest single-country pipeline in the world.

That volume translates into operational experience. Hospitals like Peking University Cancer Hospital, Ruijin Hospital in Shanghai, and Sun Yat-sen University Cancer Center in Guangzhou each manage CAR-T patients every week. Their hematology teams have treated hundreds of cases of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) — the two most serious side effects of CAR-T. Experience matters when a patient spikes a fever of 40°C at 3 a.m.

Domestic Products at a Fraction of the Price

China’s National Medical Products Administration (NMPA) has approved at least six CAR-T products. Among the most notable:

• Relmacabtagene autoleucel (Carteyva) — approved for relapsed/refractory LBCL; produced by JW Therapeutics.
• Equecabtagene autoleucel (Fucaso) — approved for relapsed/refractory multiple myeloma; produced by IASO Bio and Innovent.
• Zevorcabtagene autoleucel — approved for multiple myeloma; produced by CARsgen Therapeutics.
• Inaticabtagene autoleucel — approved for relapsed/refractory B-ALL; produced by Juventas Cell Therapy.

These are not inferior copies. They are original CAR-T constructs developed in China, with clinical trial data published in peer-reviewed journals. Fucaso, for example, reported a 98.9% overall response rate in the FUMANBA-1 study for relapsed/refractory multiple myeloma — among the highest ever recorded for a CAR-T product in that indication.

Because these products are manufactured domestically, the CAR-T therapy cost China is dramatically lower. The list price for Carteyva is approximately ¥1,200,000 (about $165,000). Fucaso is priced around ¥1,160,000 (about $160,000). Some hospitals negotiate package pricing that includes the infusion, hospitalization, and side-effect management for under $150,000 total. That is roughly one-third the US price for the drug alone.

Hospital Infrastructure Built for Cellular Therapy

Administering CAR-T is not like giving a chemotherapy infusion. It requires leukapheresis facilities to collect the patient’s T cells, certified laboratories for cell processing, and inpatient units equipped to manage severe CRS. China’s top-tier oncology hospitals have invested heavily in this infrastructure over the past five years.

Ruijin Hospital in Shanghai — affiliated with Shanghai Jiao Tong University School of Medicine — operates one of the largest hematology programs in Asia. Its Bone Marrow Transplantation and Cell Therapy Center performs more than 200 transplants annually and has dedicated CAR-T inpatient beds. Peking University Cancer Hospital in Beijing runs a specialized cellular immunotherapy ward with 24/7 intensivist coverage. These are not general hospitals dabbling in a new therapy; they are dedicated centers with established protocols.

Which Hospitals in China Offer CAR-T Therapy

The question “which hospital in China offers CAR-T therapy” has a nuanced answer. China has 35,000+ hospitals, but only a small number are certified to administer commercial CAR-T products. Certification depends on product-specific training, facility audits, and demonstrated experience managing cellular therapy toxicities.

Based on publicly available information and our work with international patients, the leading centers include:

This is not an exhaustive list. Other centers in Tianjin, Nanjing, Chengdu, and Shenzhen also administer CAR-T. The best hospital for CAR-T cell therapy in China depends on the patient’s specific diagnosis, disease stage, and whether a commercial product or clinical trial is more appropriate. A patient with triple-refractory myeloma may benefit more from a clinical trial at a research hospital than from a commercial product at a general oncology center.

For a deeper look at China’s top-ranked cancer programs, see our oncology department rankings and the Fudan-ranked top 100 hospitals list.

How Much Does CAR-T Treatment Cost in Shanghai

Shanghai is the most common entry point for international patients seeking CAR-T in China. It has the highest concentration of certified CAR-T centers, the best flight connectivity, and the most developed infrastructure for foreign visitors. So the question “how much does CAR-T treatment cost in Shanghai” deserves a direct answer.

At Ruijin Hospital or Fudan University Shanghai Cancer Center, the total cost for a commercial CAR-T course — including leukapheresis, cell manufacturing, lymphodepleting chemotherapy, CAR-T infusion, hospitalization, and management of side effects — typically ranges from $110,000 to $160,000. The variation depends on the specific product, the patient’s disease burden, the length of hospitalization, and whether complications like severe CRS require ICU admission.

For comparison:

These figures are estimates based on published list prices and typical hospitalization patterns. Actual costs vary by hospital and case complexity. No reputable center will quote a fixed price without reviewing the patient’s medical records and disease status first.

Is CAR-T Therapy Available in China for International Patients

The short answer: yes. The practical answer: it requires navigation.

China’s public hospitals do not operate like Western private clinics. You cannot simply email a hospital and book a CAR-T slot. The standard pathway for international patients looks like this:

Step 1: Remote evaluation. You send your complete medical records — pathology reports, PET/CT scans, bone marrow biopsy results, prior treatment history, and current performance status. The Chinese hematology team reviews these remotely. This is the written second opinion stage, which costs $300–$500 and determines whether CAR-T is medically appropriate and which product or trial fits best.

Step 2: Video consultation. If the written review is favorable, you speak directly with the treating hematologist via video. This costs $100–$800 depending on the seniority of the specialist and the complexity of the case. The doctor explains the proposed protocol, expected side effects, and realistic outcomes. You can ask questions — about response rates, about what happens if CRS develops, about long-term follow-up.

Step 3: Travel and in-person evaluation. You apply for an S2 visa, which is the appropriate category for short-term medical treatment in China. Family members accompanying you also apply for S2 visas. The hospital issues an official invitation letter and treatment confirmation document to support the visa application. Once in China, you undergo a full re-evaluation — fresh imaging, blood work, and possibly a repeat bone marrow biopsy — before the treatment plan is finalized.

Step 4: Leukapheresis and manufacturing. Your T cells are collected via apheresis, typically a 3–4 hour outpatient procedure. The cells are sent to the manufacturer’s facility, where they are genetically engineered and expanded. This takes 2–4 weeks depending on the product.

Step 5: Lymphodepletion and infusion. You receive a short course of chemotherapy to prepare your immune system. Then the CAR-T cells are infused. The infusion itself takes minutes. The real work begins afterward.

Step 6: Monitoring and recovery. You stay in or near the hospital for 2–4 weeks while doctors monitor for CRS, ICANS, infections, and cytopenias. Most centers require you to stay within 30 minutes of the hospital for the first month after infusion.

Booking CAR-T therapy in China as part of a medical tourism plan is possible, but it is not a single transaction. It is a coordinated, multi-week process that requires medical records translation, hospital communication, visa support, and on-the-ground logistics. We have helped patients navigate every step of this pathway through our China Medical Services coordination team.

Top CAR-T Cancer Hospitals in Beijing: What Sets Them Apart

Beijing offers a different profile than Shanghai. The capital’s strength is research depth and clinical trial access. Peking University Cancer Hospital and the Hematology Department at Peking University People’s Hospital are among the most active CAR-T centers in the country.

For patients whose disease has progressed through multiple lines of therapy, a clinical trial may be the best option. Top CAR-T cancer hospitals in Beijing run trials for novel targets — BCMA-directed CAR-T for myeloma, CD19/CD22 dual-targeting constructs for ALL, and early-phase solid tumor CAR-T studies. Trial participation sometimes covers the cost of the CAR-T product itself, leaving the patient responsible for hospitalization and supportive care. This can reduce the total financial burden to $30,000–$60,000 in some cases.

But trial participation is not guaranteed. Eligibility criteria are strict. Patients must meet specific disease characteristics, have adequate organ function, and often cannot have received prior CAR-T therapy. The evaluation process is rigorous — and appropriately so. A trial is not a discount pathway; it is a research protocol with real risks and uncertain individual benefit.

Beijing’s top CAR-T centers also tend to have longer histories with domestic products. Some of the earliest Carteyva and Fucaso post-marketing experience came from Beijing hospitals. That matters when complications arise — a team that has managed 200 cases of CRS responds differently than one that has managed 20.

Practical Considerations: Documentation, Visas, and Follow-Up

Getting to China for CAR-T is not as simple as booking a flight. Here is what you need to handle.

Medical records. Complete, organized, and translated. Chinese hematologists need: original pathology reports, all prior chemotherapy regimens with dates and doses, radiation records if applicable, PET/CT or CT reports, bone marrow biopsy results, and a current medication list. Incomplete records are the single most common reason for delayed evaluations. Spend the time to assemble everything before you contact any hospital.

Visa. The S2 visa is the correct category for short-term medical treatment in China (stays under 180 days). If your treatment and recovery will exceed 180 days, you apply for an S1 visa. The hospital’s international department will provide an official treatment confirmation letter. Do not apply for an M visa — that is for commercial and trade activities, not medical treatment. Visa processing times vary by country; allow at least 4–6 weeks.

Payment. Chinese public hospitals require prepayment. You will be asked to deposit the estimated treatment cost upfront, with adjustments as care proceeds. Payment is typically made by international bank transfer or credit card through the hospital’s international service center. Private international hospitals in China — like United Family Healthcare or Jiahui — sometimes offer direct insurance billing, but they do not administer CAR-T. CAR-T is confined to specialized public hospital centers.

Insurance. Most international health insurance plans do not cover CAR-T treatment in China. Some plans with global coverage may reimburse a portion if the treatment is deemed medically necessary and the hospital meets their accreditation standards. Check with your insurer before committing. Do not assume coverage.

Language. Even at top hospitals, day-to-day nursing and administrative staff may not speak English fluently. Physicians often read English medical literature and can communicate at a basic-to-intermediate level, but detailed clinical discussions usually require an interpreter. A bilingual medical companion — someone who handles registration, translates during consultations, and

For more medical information and treatment options in China, visit chinamedservices.com (China Medical Services).